Modified pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as EGFRWT and EGFRT790M inhibitors: Design, synthesis, and anti-cancer evaluation
作者:Eman S. Nossier、Rania A. Alasfoury、Mohamed Hagras、May El-Manawaty、Sara M. Sayed、Ibrahim M. Ibrahim、Hazem Elkady、Ibrahim H. Eissa、Heba S.A. Elzahabi
DOI:10.1016/j.molstruc.2022.133971
日期:2022.12
This study reports design and synthesis of thirteen pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as EGFR inhibitors. The antiproliferation activities were tested for all compounds against A-549, PC-3, HCT-116, and MCF-7 cell lines using doxorubicin as a reference. Compounds 6a, 6b, 7a, and 7b, which displayed the highest inhibitory percentage against all cell lines, were selected for further IC50 screening
本研究报告了作为 EGFR 抑制剂的 13 种 pyrido[2,3 - d ]pyrimidin-4(3 H )-one 衍生物的设计和合成。使用多柔比星作为参考,测试了所有化合物对 A-549、PC-3、HCT-116 和 MCF-7 细胞系的抗增殖活性。选择对所有细胞系显示最高抑制百分比的化合物6a、6b、7a和7b用于使用厄洛替尼作为参考的进一步IC 50筛选。接下来,进一步研究了四种化合物(6a、6b、7a和7b)的野生 EGFR WT和突变 EGFR T790M抑制活性。化合物7a与参考药物厄洛替尼(IC 50 = 0.051 和 0.094 µM)相比,对 EGFR WT和 EGFR T790M显示出显着的抑制活性,IC 50值分别为 0.029 和 0.055 µM 。进一步的机制研究表明,化合物7a能够在前 G1 期和 S 期阻止细胞周期,并将总细胞凋亡提高 21.82